Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PPARD | Q03181 | 6/20 | 0.48 |
| ▸ | PPARA | Q07869 | 6/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3716560 | 1.00 | TSHR (0.60) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1673084 | 1.00 | TSHR (0.60) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL9238670 | 1.00 | TSHR (0.60) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL94566 | 0.90 | — | — | |
| SCHEMBL5168783 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL13855529 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7687851 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL20475058 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL7693275 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 | |
| SCHEMBL1163681 | 0.79 | TSHR (0.67) | TSHRLMNANFKB1PMP22GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012057751-A1 | CROSSLINKED CELLULOSIC POLYMERS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2012-05-03 | — | — | WO | claimed |
| US-20190209697-A1 | CELLS LABELLED WITH LIPID CONJUGATES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-11 | — | — | US | disclosed |
| EP-3370764-A1 | CELLS LABELLED WITH LIPID CONJUGATES AND METHODS OF USE THEREOF | The Regents of The University of California (US) | 2018-09-12 | — | — | EP | disclosed |
| WO-2017079419-A1 | CELLS LABELLED WITH LIPID CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-05-11 | — | — | WO | disclosed |
| US-8637468-B2 | Synthetic cholesterylamine-linker derivatives for agent delivery into cells | THE UNIVERSITY OF KANSAS (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130142763-A1 | CROSSLINKED CELLULOSIC POLYMERS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-20120208771-A1 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | THE PENN STATE RESEARCH FOUNDATION (US) | 2012-08-16 | — | — | US | disclosed |
| WO-2012057751-A1 | CROSSLINKED CELLULOSIC POLYMERS | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2012-05-03 | — | — | WO | disclosed |
| WO-2011019942-A2 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | UNIVERSITY OF KANSAS (US) | 2011-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209697-A1 | CELLS LABELLED WITH LIPID CONJUGATES AND METHODS OF USE THEREOF | NPC1L1, CETP, LIPA | TSHR 3346/4885LMNA 121/4885NFKB1 3538/4885 |
| US-20120208771-A1 | SYNTHETIC CHOLESTERYLAMINE-LINKER DERIVATIVES FOR AGENT DELIVERY INTO CELLS | NPC1L1, CETP, CYP46A1 | TSHR 3260/4885LMNA 339/4885NFKB1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.